Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age30-60
SponsorVA Office of Research and Development
About this trial
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
Eligibility criteria
Qualifiers
Body mass index (BMI) 30-45 kg/m2
30-60 years of age at randomization
Evidence of arterial stiffening (defined as Carotid femoral PWV>age-predicted) at screening visit (PMID: 20530030)
Disqualifiers
Unable to provide consent
Diabetes mellitus
Uncontrolled hypertension (>180/90mmHg) or systolic <100mmHg at screening visit
Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
Trial design
Treatments tested in this trial
- Empagliflozin
- Placebo
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
VA Office of Research and Development
Lead sponsor
University of Missouri-Columbia
Collaborator
Source ClinicalTrials.gov